Last reviewed · How we verify
Inactivated Split Influenza Vaccine
This inactivated split influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against influenza virus strains by presenting viral antigens without infectious virus.
This inactivated split influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against influenza virus strains by presenting viral antigens without infectious virus. Used for Influenza prevention in adults and children.
At a glance
| Generic name | Inactivated Split Influenza Vaccine |
|---|---|
| Sponsor | St. Petersburg Research Institute of Vaccines and Sera |
| Drug class | Inactivated split influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated (killed) influenza virus particles that have been split into component antigens. When administered, these antigens are recognized by the immune system, triggering both humoral (antibody) and cellular immune responses. This prepares the body to recognize and neutralize circulating influenza viruses, reducing infection risk and disease severity.
Approved indications
- Influenza prevention in adults and children
Common side effects
- Injection site soreness or erythema
- Myalgia
- Headache
- Low-grade fever
- Fatigue
Key clinical trials
- Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women (PHASE3)
- High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients (PHASE2)
- Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older (PHASE3)
- High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients (PHASE2)
- Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age (PHASE3)
- Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (PHASE3)
- Clinical Trials of Quadrivalent Influenza Vaccine (PHASE1, PHASE2)
- A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: